P2116
Pirfenidone
≥97% (HPLC), powder, antifibrotic agent
Synonym(s):
5-Methyl-1-phenyl-2-(1H)-pyridone
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C12H11NO
CAS Number:
Molecular Weight:
185.22
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Pirfenidone, ≥97% (HPLC)
Quality Level
assay
≥97% (HPLC)
form
powder
solubility
H2O: >10 mg/mL at 60 °C (warming for 30 minutes), DMSO: >20 mg/mL
originator
Shionogi
SMILES string
O=C(C=CC(C)=C1)N1C2=CC=CC=C2
InChI
1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
InChI key
ISWRGOKTTBVCFA-UHFFFAOYSA-N
General description
Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is a synthetic derivative of pyridine.
Application
Pirfenidone has been used:
- as a post-operative eye drop in rabbits to analyse its antifibrotic effect to improve glaucoma filtration surgery
- as an anti-scarring agent to examine whether it affects the foreign body reaction after glaucoma drainage device (GDD) implantation in a rabbit
- to test its antifibrotic potential in primary cultures of human orbital fibroblasts (hOFs)
- as tumor necrosis factor (TNFα) inhibitor to study its effect in hypoxia
Biochem/physiol Actions
Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF). It helps to decrease the weakening of lung function decline and ameliorate progression-free survival. Pirfenidone can repress the multiplication and contraction of collagen of human tenon′s fibroblasts.
Inhibits collagen production and fibroblast proliferation.
Pirfenidone inhibits collagen production and fibroblast proliferation. It has shown antifibrotic and anti-inflammatory properties in variety of animal models of pulmonary fibrosis, and in clinical trials.
Features and Benefits
This compound was developed by Shionogi. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Pirfenidone
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
Arata Azuma
Therapeutic advances in respiratory disease, 6(2), 107-114 (2012-02-16)
Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3-5 years, and the
Huzaifa I Adamali et al.
Drug design, development and therapy, 6, 261-272 (2012-10-12)
Over the past decade, there has been a cohesive effort from patients, physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and pathogenesis has improved, the
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster L H, et al.
European Respiratory Review, 26(146), 170057-170057 (2017)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| P2116-10MG | 04061834362500 |
| P2116-50MG | 04061834362517 |